WO2011097273A8 - Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine - Google Patents
Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine Download PDFInfo
- Publication number
- WO2011097273A8 WO2011097273A8 PCT/US2011/023434 US2011023434W WO2011097273A8 WO 2011097273 A8 WO2011097273 A8 WO 2011097273A8 US 2011023434 W US2011023434 W US 2011023434W WO 2011097273 A8 WO2011097273 A8 WO 2011097273A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cysteine
- acetyl
- compositions
- alcoholic fatty
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title 2
- 229940090949 docosahexaenoic acid Drugs 0.000 title 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is related to methods and compositions for treating non-alcoholic fatty liver disease (NAFLD), and methods of enhancing liver health and/or liver function, in a subject in need thereof, the methods comprising administering to the subject about 200 mg to about 12 g of docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA), and an effective amount of N-acetyl L-cysteine (NAC).
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30082210P | 2010-02-02 | 2010-02-02 | |
US61/300,822 | 2010-02-02 | ||
US30595210P | 2010-02-18 | 2010-02-18 | |
US61/305,952 | 2010-02-18 | ||
US36734910P | 2010-07-23 | 2010-07-23 | |
US61/367,349 | 2010-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011097273A1 WO2011097273A1 (en) | 2011-08-11 |
WO2011097273A8 true WO2011097273A8 (en) | 2011-10-20 |
Family
ID=44355749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/023434 WO2011097273A1 (en) | 2010-02-02 | 2011-02-02 | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011097273A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2777827C (en) | 2009-10-30 | 2020-08-18 | Retrotope, Inc. | Alleviating oxidative stress disorders with pufa derivatives |
KR102020579B1 (en) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Impaired energy processing disorders and mitochondrial deficiency |
WO2012148929A2 (en) * | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Disorders implicating pufa oxidation |
AU2012249921B2 (en) | 2011-04-26 | 2017-06-08 | Biojiva Llc | Oxidative retinal diseases |
KR102020611B1 (en) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Neurodegenerative disorders and muscle diseases implicating pufas |
WO2013115636A1 (en) * | 2012-02-02 | 2013-08-08 | Universiti Sains Malaysia | Composition for the treatment and/or prevention of fatty liver disease |
KR20170093966A (en) * | 2014-12-15 | 2017-08-16 | 디에스엠 아이피 어셋츠 비.브이. | Treatment for non-alcoholic fatty liver diseases |
ES2871130T3 (en) | 2015-11-23 | 2021-10-28 | Retrotope Inc | Site-specific isotopic labeling of 1,4-diene systems |
JOP20190146A1 (en) * | 2016-12-19 | 2019-06-18 | Axcella Health Inc | Amino acid compositions and methods for the treatment of liver diseases |
KR20200039748A (en) | 2017-08-14 | 2020-04-16 | 악셀라 헬스 인크. | Amino acid composition for treatment of liver disease |
US20210212936A1 (en) * | 2018-06-01 | 2021-07-15 | Baxter International Inc. | Parenteral nutrition formulation |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
EP3866759A1 (en) * | 2018-10-18 | 2021-08-25 | DS Biopharma Limited | Dgla and/or 15-hetre for treating inflammatory, fibrotic, and proliferative conditions |
CN109464454B (en) * | 2018-11-29 | 2021-07-02 | 天津中医药大学 | Application of brown algae oligosaccharide in preparation of medicine for treating or preventing liver injury |
EP4014758A4 (en) | 2019-08-13 | 2023-08-16 | Team Foods Colombia S.A. | Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld) |
CN110846346B (en) * | 2019-11-26 | 2021-06-22 | 瞿瀚鹏 | Microbial oil rich in Sn-2 DHA, and preparation method and application thereof |
EP4107163A1 (en) | 2020-02-21 | 2022-12-28 | Retrotope, Inc. | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2377414A1 (en) * | 1999-06-15 | 2000-12-21 | John D. Potter | Nutrient formulations for disease reduction, and related treatment and component screening methods |
US20090182022A1 (en) * | 2006-01-05 | 2009-07-16 | Reliant Pharmaceuticals | Treatment of Fatty Liver |
JP2010532418A (en) * | 2007-06-29 | 2010-10-07 | マーテック バイオサイエンシーズ コーポレーション | Process for producing and purifying ester of polyunsaturated fatty acid |
-
2011
- 2011-02-02 WO PCT/US2011/023434 patent/WO2011097273A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2011097273A1 (en) | 2011-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011097273A8 (en) | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine | |
WO2008018043A3 (en) | Methods of improving bone health and muscle health | |
GB2459809A (en) | Fatty acid formulations and methods of use thereof | |
NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
WO2011097276A8 (en) | Methods and compositions for treating arthritis with docosahexaenoic acid | |
CO6470839A2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF EMPLOYMENT | |
NZ757815A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
WO2007058538A3 (en) | Composition with docosapentaenoic acid | |
GT201200056A (en) | CONJUGATES OF NIACINA AND FATTY ACIDS AND THEIR USES | |
MY165142A (en) | Metabolic imprinting effects of specifically designed lipid component | |
MX2016008270A (en) | Lipid comprising long chain polyunsaturated fatty acids. | |
EA200970238A1 (en) | APPLICATION OF OILS WITH DPA (n-6) IN CHILDREN'S FOOD | |
BRPI0418921A (en) | use of polyunsaturated fatty acids, nutritional composition, and use of a | |
PH12017500074A1 (en) | Nutritional compositions containing oil blends and uses thereof | |
NZ609527A (en) | N1/n2-lactam acetyl-coa carboxylase inhibitors | |
RU2013146517A (en) | COMPOSITIONS AND METHODS SUITABLE FOR FACILITATION OF AGE DISEASES | |
MX2014000770A (en) | Fatty acid compositions. | |
BR112014019927A8 (en) | nutritional formula, method of preparing said formula prior to ingestion by an individual, use of said formula, device for preparing it and container | |
PH12018500090A1 (en) | Nutritional compositions and methods for promoting cognitive development | |
WO2007103160A3 (en) | Stearidonic acid for improving cardiovascular health | |
MX2013010076A (en) | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE. | |
BRPI0512528A (en) | use of polyunsaturated fatty acids, nutritional composition, and use of a composition | |
PH12018500035A1 (en) | Nutritional compositions and methods for promoting cognitive development | |
PH12018500036A1 (en) | Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11740286 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11740286 Country of ref document: EP Kind code of ref document: A2 |